Author

Kai-Yi Tzou

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Targeting the DNHD1‑HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability.

Prostate cancer progression toward an aggressive, therapy‑resistant disease state remains a major clinical challenge, indicating a need to identify novel molecular drivers of such progression and actionable therapeutic targets. The present study analyzed the role of dynein heavy chain domain 1 (DNHD1), a previously unc...

An-Nie-On-Nei Lee, Chia-Chang Wu, Su-Wei Hu et al. · Oncology Report · 0 citations

Review Aug 2026

Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.

The biological functions, immunoregulatory mechanisms, and therapeutic potential of Tα1 in oncology are summarized to provide an updated perspective on the role of Tα1 as a potential adjunctive immunomodulatory agent in modern cancer immunotherapy.

Sih-Chi Chuang, Pei-Chia Hung, Lekshmi Rethi et al. · European Journal of Pharmaco... · 0 citations

Open access Sep 2026

A CD44-targeted PDA/ZnO redox-active nanocomposite that couples chemotherapy with mitochondrial stress and tumor immune remodeling

Bladder cancer therapy is frequently limited by inefficient drug retention and adaptive immune resistance within a hypoxic tumor microenvironment. Here, we report a CD44-targeted, fully synthetic nanocomposite (HPPZC) that converts chemotherapy into a mitochondria-associated therapeutic strategy accompanied by tumor im...

Andrew E.-Y. Chuang, Szu-Yu Tung, Kai-Yi Tzou et al. · Journal of Nanobiotechnology · 0 citations